Key Highlights
- 5.153 million is the USD Revenue Vivos Therapeutics, Inc. (NASDAQ:VVOS) reported for the second quarter of 2026, up 35% from USD 3.82 million, with service revenue of USD 3.798 million nearly doubling.
- 0.31 is the USD net loss per share for the second quarter of 2026, improved from 0.55 a year earlier, on a net loss of USD 5.523 million and 17,681,945 weighted average shares.
- 1.774 million is the USD cash balance on June 30, 2026, set against calculated total Debt of USD 8.138 million and a stockholders' Deficit of USD 3.815 million.
- 12 million is the USD stated value of Series C preferred stock issued in October 2026, expected to lift Equity by more than USD 10 million after Nasdaq confirmed compliance on October 20, 2026.
What Investors Expect From Vivos Therapeutics, Inc. (NASDAQ:VVOS) on November 16, 2026
Vivos Therapeutics, Inc. is scheduled to report third quarter 2026 results on November 16, 2026, covering the quarter ended September 30, 2026. The comparison base is demanding. In the third quarter of 2025 it reported revenue of USD 6.783 million, Gross Profit of USD 3.937 million at a 58% margin, an operating loss of USD 4.734 million and a net loss of USD 5.4 million, or USD 0.49 per share on 10,963,590 weighted average shares. Service revenue was USD 4.588 million then, versus USD 3.798 million in the second quarter of 2026.
The Rationale: Last Reported Quarter and Management Outlook for Vivos Therapeutics, Inc. (NASDAQ:VVOS)
For the quarter ended June 30, 2026, reported on August 14, 2026, revenue rose 35% to USD 5.153 million. Product revenue fell to USD 1.355 million from USD 1.885 million. Gross profit was USD 2.953 million, a 57% Margin against 55%. Operating expenses were USD 7.778 million versus USD 6.975 million, producing an operating loss of USD 4.825 million. Net loss was USD 5.523 million, or USD 0.31 per share. The company has not issued numeric guidance. Chief executive Kirk Huntsman called the quarter a watershed moment, citing expanded facilities, more providers, higher Nevada referrals and cardiology Partnership talks in Florida and Arizona. Management expects significant revenue gains in the third quarter and beyond, without quantifying them.
Valuation, Liquidity and Risks for Vivos Therapeutics, Inc. (NASDAQ:VVOS)
Cash stood at USD 1.774 million on June 30, 2026, versus USD 2.029 million at year-end. Debt comprised USD 7.772 million current and USD 0.366 million long-term, a calculated total of USD 8.138 million. Total liabilities were USD 28.13 million against Assets of USD 24.144 million, with 14,531,617 common shares outstanding. Nasdaq Listing Rule 5550(b)(1) requires stockholders' equity of at least USD 2.5 million, and on October 20, 2026 the exchange confirmed compliance. The company issued 12,000 Series C preferred shares, convertible at USD 0.15 into up to 80,000,000 common shares, for an 11% stake in SOD Sciences. A 19.99% exchange cap applies pending stockholder approval. The stock closed at USD 0.1406 on October 20, 2026, so dilution and listing standards remain central risks.
Where Things Stand
Vivos Therapeutics, Inc. (NASDAQ:VVOS) enters its November 16, 2026 report with revenue momentum in sleep services but thin liquidity. Second quarter revenue of USD 5.153 million grew 35% and the per-share loss narrowed to USD 0.31, yet cash of USD 1.774 million trails a quarterly operating loss of USD 4.825 million. The Series C issuance supports equity compliance, but conversion into up to 80,000,000 shares could dilute holders. Investors will focus on third quarter service revenue against USD 6.783 million a year earlier, any cash update, and commentary on stockholder approval, partnerships and the path toward breakeven operations.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...